Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 1
2001 1
2004 1
2005 2
2006 1
2009 3
2010 1
2011 1
2012 1
2014 1
2015 1
2016 1
2018 2
2019 6
2020 1
2021 5
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Bone impact after two years of low-dose oral contraceptive use during adolescence.
Orsolini LR, Goldberg TBL, Caldeirão TD, Cristiane da Silva C, Rizzo ADCB, Biason TP, Teixeira AS, Carvalho Nunes HR. Orsolini LR, et al. PLoS One. 2023 Jun 8;18(6):e0285885. doi: 10.1371/journal.pone.0285885. eCollection 2023. PLoS One. 2023. PMID: 37289781 Free PMC article. Clinical Trial.
RESULTS: Incorporation of bone mass was greater in non-users at all sites analyzed (4.85 g in lumbar Bone mineral content (BMC)) when compared to adolescents of the COC1 and COC2 groups, with a respective increase of 2.15 g and loss of 0.43g in lumbar BMC (P = 0.001). When …
RESULTS: Incorporation of bone mass was greater in non-users at all sites analyzed (4.85 g in lumbar Bone mineral content (BMC)) when compar …
Sarcomas and pharmacogenetics.
Biason P, Toffoli G. Biason P, et al. Pharmacogenomics. 2005 Sep;6(6):585-601. doi: 10.2217/14622416.6.6.585. Pharmacogenomics. 2005. PMID: 16142999 Review.
., cytochrome P450 and glutathione-S-transferase), transporter proteins (reduced folate carrier and P-glycoprotein) or target proteins (thymidylate synthase, methylenetetrahydrofolate reductase, dihydrofolate reductase, and c-KIT) may be responsible for an altered clinical …
., cytochrome P450 and glutathione-S-transferase), transporter proteins (reduced folate carrier and P-glycoprotein) or target protein …
Low-dose ketoconazole treatment in hirsute women.
Sonino N, Scaroni C, Biason A, Boscaro M, Mantero F. Sonino N, et al. J Endocrinol Invest. 1990 Jan;13(1):35-40. doi: 10.1007/BF03348578. J Endocrinol Invest. 1990. PMID: 2138647
At 3 months, DHEA-S decreased from 9.9 +/- 1.0 (mean +/- SE) to 6.9 +/- 1.0 mumol/L (p less than 0.01), androstenedione from 13.3 +/- 1.5 to 8.3 +/- 1.3 nmol/L (p less than 0.005), and testosterone from 4.2 +/- 0.4 to 3.1 +/- 0.4 nmol/L (p less than 0.05). .. …
At 3 months, DHEA-S decreased from 9.9 +/- 1.0 (mean +/- SE) to 6.9 +/- 1.0 mumol/L (p less than 0.01), androstenedione from 13.3 +/- …
A Multicenter Evaluation of Ceftolozane/Tazobactam Treatment Outcomes in Immunocompromised Patients With Multidrug-Resistant Pseudomonas aeruginosa Infections.
Hart DE, Gallagher JC, Puzniak LA, Hirsch EB; C/T Alliance to deliver Real-world Evidence (CARE). Hart DE, et al. Open Forum Infect Dis. 2021 Mar 6;8(3):ofab089. doi: 10.1093/ofid/ofab089. eCollection 2021 Mar. Open Forum Infect Dis. 2021. PMID: 33796600 Free PMC article.
CONCLUSIONS: Of 69 immunocompromised patients treated with C/T for MDR P. aeruginosa, clinical cure was achieved in 68% and mortality was 19%, consistent with other reports on a cross-section of patient populations. C/T represents a promising agent for treatment of P …
CONCLUSIONS: Of 69 immunocompromised patients treated with C/T for MDR P. aeruginosa, clinical cure was achieved in 68% and mortality …
Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization.
Schirripa M, Biason P, Lonardi S, Pella N, Pino MS, Urbano F, Antoniotti C, Cremolini C, Corallo S, Pietrantonio F, Gelsomino F, Cascinu S, Orlandi A, Munari G, Malapelle U, Saggio S, Fontanini G, Rugge M, Mescoli C, Lazzi S, Reggiani Bonetti L, Lanza G, Dei Tos AP, De Maglio G, Martini M, Bergamo F, Zagonel V, Loupakis F, Fassan M. Schirripa M, et al. Clin Cancer Res. 2019 Jul 1;25(13):3954-3961. doi: 10.1158/1078-0432.CCR-19-0311. Epub 2019 Apr 9. Clin Cancer Res. 2019. PMID: 30967421
RESULTS: Class 3 BRAF-mutated mCRC was more frequently left sided (P = 0.0028), pN0 (P = 0.0159), and without peritoneal metastases (P = 0.0176) compared with class 1, whereas class 2 cases were similar to class 1. Hazard ratio for OS, as compared with BRAF w …
RESULTS: Class 3 BRAF-mutated mCRC was more frequently left sided (P = 0.0028), pN0 (P = 0.0159), and without peritoneal metas …
CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer.
Loupakis F, Biason P, Prete AA, Cremolini C, Pietrantonio F, Pella N, Dell'Aquila E, Sperti E, Zichi C, Intini R, Dadduzio V, Schirripa M, Bergamo F, Antoniotti C, Morano F, Cortiula F, De Maglio G, Rimassa L, Smiroldo V, Calvetti L, Aprile G, Salvatore L, Santini D, Munari G, Salmaso R, Guzzardo V, Mescoli C, Lonardi S, Rugge M, Zagonel V, Di Maio M, Fassan M. Loupakis F, et al. Br J Cancer. 2019 Oct;121(7):593-599. doi: 10.1038/s41416-019-0560-0. Epub 2019 Sep 2. Br J Cancer. 2019. PMID: 31474758 Free PMC article.
RESULTS: CDX2 loss conferred worse OS (HR = 1.72, 95%CI 1.03-2.86, p = 0.036), as well as high CK7 expression (HR = 2.17, 95%CI 1.10-4.29, p = 0.026). According to Consensus Molecular Subtypes (CMS), CMS1 patients had better OS compared to CMS2-3/CMS4 (HR = 0.37, 95 …
RESULTS: CDX2 loss conferred worse OS (HR = 1.72, 95%CI 1.03-2.86, p = 0.036), as well as high CK7 expression (HR = 2.17, 95%CI 1.10- …
Synaptophysin expression in V600EBRAF-mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis.
Fassan M, Milione M, Maddalena G, Cremolini C, Schirripa M, Pietrantonio F, Pella N, Dell'Aquila E, Sperti E, Zichi C, Bergamo F, Volante M, Boccaccino A, Morano F, Cortiula F, De Maglio G, Rimassa L, Smiroldo V, Calvetti L, Aprile G, Salvatore L, Santini D, Salmaso R, Centonze G, Biason P, Borga C, Lonardi S, Zagonel V, Dei Tos AP, Di Maio M, Loupakis F. Fassan M, et al. Eur J Cancer. 2021 Mar;146:145-154. doi: 10.1016/j.ejca.2021.01.016. Epub 2021 Feb 16. Eur J Cancer. 2021. PMID: 33607478
At multivariate analysis, high synaptophysin expression was a negative independent prognostic factor for both PFS (HR = 2.00, 95% confidence interval [CI] 1.21-3.33, p = 0.006) and OS (HR = 2.27, 95% CI 1.35-3.85, p = 0.001). CONCLUSIONS: Among BRAFmt mCRCs, synapto …
At multivariate analysis, high synaptophysin expression was a negative independent prognostic factor for both PFS (HR = 2.00, 95% confidence …
Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes.
Loupakis F, Depetris I, Biason P, Intini R, Prete AA, Leone F, Lombardi P, Filippi R, Spallanzani A, Cascinu S, Bonetti LR, Maddalena G, Valeri N, Sottoriva A, Zapata L, Salmaso R, Munari G, Rugge M, Dei Tos AP, Golovato J, Sanborn JZ, Nguyen A, Schirripa M, Zagonel V, Lonardi S, Fassan M. Loupakis F, et al. Oncologist. 2020 Jun;25(6):481-487. doi: 10.1634/theoncologist.2019-0611. Epub 2020 Jan 22. Oncologist. 2020. PMID: 31967692 Free PMC article.
RESULTS: In the exploratory cohort, an increasing number of TILs correlated to higher TMB (Pearson's test, p = .0429). In the whole cohort, median number of TILs was 3.6 in responders compared with 1.8 in nonresponders (Mann-Whitney test, p = .0448). RR was 70.6% in …
RESULTS: In the exploratory cohort, an increasing number of TILs correlated to higher TMB (Pearson's test, p = .0429). In the whole c …
A Real-World Application of Liquid Biopsy in Metastatic Colorectal Cancer: The Poseidon Study.
Procaccio L, Bergamo F, Daniel F, Rasola C, Munari G, Biason P, Crucitta S, Barsotti G, Zanella G, Angerilli V, Magro C, Paccagnella S, Di Antonio V, Loupakis F, Danesi R, Zagonel V, Del Re M, Lonardi S, Fassan M. Procaccio L, et al. Cancers (Basel). 2021 Oct 13;13(20):5128. doi: 10.3390/cancers13205128. Cancers (Basel). 2021. PMID: 34680277 Free PMC article.
RESULTS: A total of 33 mCRC patients were included. Mean T1 and T2 was 7 and 22 days (d), respectively (p < 0.00001). T2 included a mean time for archival tissue recovery of 17 d. ...

RESULTS: A total of 33 mCRC patients were included. Mean T1 and T2 was 7 and 22 days (d), respectively (p < 0.00001). T2 included

…
Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy.
Cecchin E, Agostini M, Pucciarelli S, De Paoli A, Canzonieri V, Sigon R, De Mattia E, Friso ML, Biason P, Visentin M, Nitti D, Toffoli G. Cecchin E, et al. Pharmacogenomics J. 2011 Jun;11(3):214-26. doi: 10.1038/tpj.2010.25. Epub 2010 Apr 6. Pharmacogenomics J. 2011. PMID: 20368715
Patients bearing at least one variant allele had a lower chance to get TRG 2 (OR = 0.46 95% CI 0.23-0.90, P = 0.024; and OR = 0.48 95% CI 0.24-0.96, P = 0.034; respectively). ...On the basis of CART results, patients were categorized into three groups according to t …
Patients bearing at least one variant allele had a lower chance to get TRG 2 (OR = 0.46 95% CI 0.23-0.90, P = 0.024; and OR = 0.48 95 …
29 results